Zurueck zur Suche

Reporte zur Charge U7675DB

Verknuepft ueber VAERS_ID mit VAERSDATA, Vax und Symptoms

2Reporte angezeigt
0Todesfaelle
0Hospitalisiert
0Lebensbedrohlich
0Bleibende Schaeden
FL 1 NH 1

VAERS 2719340

SANOFI PASTEUR · DTAP + IPV (QUADRACEL) · Charge U7675DB

gering
Staat
FL
Alter
16,0
Geschlecht
M
Eingang
30.11.2023
Impfdatum
21.11.2023
Beginn
21.11.2023
Tage bis Beginn
0,0
Dosis
UNK
Route/Site
OT / RA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Medication error No adverse event Product administered to patient of inappropriate age

Symptomtext

16 year old patient was accidentally administered with quadracel with no reported adverse event; Initial information received on 21-Nov-2023 regarding an unsolicited valid non-serious case received from a other health professional. This case involves a 16 years old male patient who was accidentally administered with Diphtheria-15/Tetanus/5 Hybrid AC Pertussis/IPV (MRC5) vaccine [QUADRACEL] with no reported adverse event. The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. Concomitant medications included Influenza vaccine (FLU VACCINE VII) and Meningococcal vaccine A/C/Y/W CONJ (TET TOX) (Menquadfi) for Prophylactic vaccination. On 21-Nov-2023, the patient received 0.5 ml dose of suspect Diphtheria-15/Tetanus/5 Hybrid AC Pertussis/IPV (MRC5) vaccine Suspension for injection of lot U7675DB and Expiry: 30-Sep-2025 via intramuscular route in the right arm as prophylactic vaccination (immunization). On 21-Nov-2023, the patient was accidentally administered with Diphtheria-15/Tetanus/5 Hybrid AC Pertussis/IPV (MRC5) vaccine with no reported adverse event (product administered to patient of inappropriate age) (latency: same day). No lab data was reported. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Medication error
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
FLU VACCINE VII; MENQUADFI
Allergien
-
Vorherige Impfungen
-

VAERS 2703563

UNKNOWN MANUFACTURER · MENINGOCOCCAL (NO BRAND NAME) · Charge U7675DB

gering
Staat
NH
Alter
6,0
Geschlecht
M
Eingang
27.10.2023
Impfdatum
17.10.2023
Beginn
17.10.2023
Tage bis Beginn
0,0
Dosis
UNK
Route/Site
OT / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Medication error No adverse event Wrong product administered

Symptomtext

Patient was not supposed to receive a dose of Menquadfi with no reported adverse event; Initial information received on 18-Oct-2023 regarding an unsolicited valid non-serious case received from other healthcare professional. This case involves a 6 years old male patient who was not supposed to receive a dose of Meningococcal A-C-Y-W135 (T CONJ) vaccine [Menquadfi] with no reported adverse event. The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. On 17-Oct-2023, the patient received 0.5 ml dose (frequency: once) of suspect Meningococcal A-C-Y-W135 (T CONJ) vaccine Solution for injection of lot U7675DB via route : (abbreviation not known; requested) in unknown administration site for immunization; however, patient was not supposed to receive a dose of menquadfi (wrong product administered) (latency: same day). No lab data was reported. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Medication error
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-